Market capitalization | €1.54b |
Enterprise Value | €-2.01b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 3.81 |
EV/Sales (TTM) EV/Sales | -3.69 |
P/S ratio (TTM) P/S ratio | 2.84 |
P/B ratio (TTM) P/B ratio | 0.53 |
Sales growth (TTM) Sales growth | -5.75% |
Turnover (TTM) Turnover | €543.97m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
14 Analysts have issued a Galapagos forecast:
14 Analysts have issued a Galapagos forecast:
Mar '24 |
+/-
%
|
||
Turnover | 544 544 |
1%
1%
|
|
Gross income | 526 526 |
2%
2%
|
|
EBITDA | - - |
-
|
EBIT (operating result) EBIT | -209 -209 |
23%
23%
|
Net profit | -153 -153 |
16%
16%
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Head office | Belgium |
CEO | Paulus Stoffels |
Employees | 1,123 |
Founded | 1999 |
Website | www.glpg.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.